RCO Score Is Clinically, Prognostically Relevant in Secondary Myelofibrosis

The Reticulin, Collagen, Osteosclerosis (RCO) score, previously developed for primary myelofibrosis (PMF), is both clinically and prognostically relevant in secondary myelofibrosis (SMF), according to a study presented at the 65th ASH Annual Meeting & Exposition, which is taking place December 9-12 in San Diego, California.

In this retrospective, single-center study, Giacomo Coltro, MD, and colleagues analyzed 72 patients with SMF. They then analyzed clinical, genetic, and prognostic correlates, while also analyzing RCO scores using 2 independent histopathologists.

The study showed that higher RCO scores were linked to lower hemoglobin values (Pearson’s r, −0.3; P=.0173), lower platelet counts (Pearson’s r, −0.3; P=.0106), and higher LDH values (Pearson’s r, 0.3; P=.0308). Also, multivariate analysis showed that the predictive relevance of the RCO score was independent of stratification based on the MYSEC Prognostic Model (MYSEC-PM) risk calculator. The study also found that the integration of dichotomous RCO scores >6 or <6 (RCOs⁶) enhanced the performance of the MYSEC-PM.

“The results of the current study indicate that the RCO [score], although formerly developed for [patients] with PMF, is clinically and prognostically relevant in SMF. Most importantly, we showed that integrating the discrete RCOs⁶ into the SMF-specific MYSEC-PM can significantly improve the predictive performance of the prognostic model,” the researchers concluded.

Reference

Coltro G, Santi R, Atanasio A, et al. The Reticulin, Collagen, Osteosclerosis (RCO) score is clinically and prognostically relevant in patients with secondary myelofibrosis (SMF). Abstract #1821. Presented at the 65th ASH Annual Meeting & Exposition; December 9-12, 2023; San Diego, California.